Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon6 and 5 bp deletion in exon6.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CRAT, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CRAT or carnitine O-acetyltransferase is an enzyme that catalyzes the reversible transfer of acyl groups from acyl-CoA to carnitine. This protein has a molecular weight of approximately 70 kDa. CRAT is mainly expressed in the mitochondria peroxisomes and some degree in the cytosol of tissues with high energy demands such as the heart liver and skeletal muscle. It plays a critical role in modulating the concentration of acyl-CoA and carnitine compounds within these cellular compartments which impacts lipid metabolism significantly.
Biological function summary
Carnitine O-acetyltransferase facilitates the transportation of acyl groups across the mitochondrial membranes influencing energy homeostasis by converting excess acyl-CoA to acylcarnitine. It does not form part of a larger protein complex but operates as a singular catalytic entity. The enzyme's function in balancing acyl-CoA and free CoA levels is essential for maintaining cellular metabolic flexibility allowing cells to switch energy sources efficiently when necessary.
Pathways
Carnitine O-acetyltransferase sits within the fatty acid oxidation pathway aiding in the linkage between carbohydrate and lipid metabolism. It interacts with proteins like carnitine palmitoyltransferase I (CPT I) and acetyl-CoA carboxylase important for controlling the flow of long-chain fatty acids into mitochondria for β-oxidation. The action of CRAT impacts the ketogenesis pathway assisting in maintaining energy production through conversion of stored fats when glucose is not readily available.
Carnitine O-acetyltransferase influences conditions like insulin resistance and metabolic syndrome owing to its role in lipid metabolism. Dysregulation of CRAT function disrupts fatty acid utilization which can lead to the development of these metabolic conditions. Additionally CRAT associates with proteins such as acetyl-CoA carboxylase and AMP-activated protein kinase both of which are implicated in the regulation of these metabolic pathways and disorders.
